化学
基因亚型
药理学
生物利用度
激酶
自身免疫性疾病
酶
贾纳斯激酶
炎症
酶抑制剂
生物化学
Janus激酶2
生物活性
结构-活动关系
口服活性
体外
蛋白激酶A
药物发现
托法替尼
药代动力学
信号转导
Janus激酶3
体内
蛋白激酶C
作者
卓金聪,Yunlong Li,Ding‐Quan Qian,David M. Burns,Song Mei,Maria Rafalski,Meizhong Xu,Ganfeng Cao,Yongchun Pan,Zhongjiang Jia,Ravi K. Jalluri,Leslie B. Epling,Gustavo Fenalti,Marc C. Deller,Jessica Procak,M.B. Covington,Xin He,Robert Collins,Matthew Stubbs,Krista Burke
标识
DOI:10.1021/acs.jmedchem.5c03753
摘要
Abstract Aberrant JAK2 signaling is a key driver in cancers such as myeloproliferative neoplasms (MPNs), whereas JAK1 acts as a central mediator of autoimmune and inflammatory diseases. Since JAK2 supports blood cell production, its inhibition can lead to anemia and other cytopenias, making selective JAK1 inhibition a potentially safer therapeutic strategy opposed to dual JAK1/JAK2 inhibition. We initially identified novel scaffold 9, which selectively inhibited JAK1 over JAK2. Iterative breakthroughs led to the discovery of povorcitinib (INCB054707, 22), which showed improved pharmacokinetics due to intramolecular hydrogen bonding of the amide moiety and a reduced ring size in the hinge binding motif. Protein crystallography suggested that JAK1 selectivity was conferred by the amide’s alkyl group accessing a small lipophilic groove formed by the P-loop conformation of JAK1 that was distinct from JAK2. In murine arthritis models, povorcitinib demonstrated dose-dependent efficacy and reduced inflammatory signaling, supporting its therapeutic potential in immunological disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI